Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes

Approach to assessing the economic impact of insulin-related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool

(2015) W. A. Parekh et al.   DIABETIC MEDICINE

Hypoglycemia in Older People - A Less Well Recognized Risk Factor for Frailty

(2015) Ahmed H Abdelhafiz et al.   Aging and Disease

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

(2014) John B. Buse et al.   DIABETES CARE

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

(2013) L. Meneghini et al.   DIABETES CARE

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes

(2013) Stephen C.L. Gough et al.   DIABETES CARE

Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

(2013) E. R. Seaquist et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes

(2013) L. Meneghini et al.   DIABETES OBESITY & METABOLISM

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

(2013) A. Philis-Tsimikas et al.   DIABETES OBESITY & METABOLISM

Treat-to-target trials: uses, interpretation and review of concepts

(2013) A. J. Garber   DIABETES OBESITY & METABOLISM

Self-reported non-severe hypoglycaemic events in Europe

(2013) C. G. Östenson et al.   DIABETIC MEDICINE

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

(2013) H. W. Rodbard et al.   DIABETIC MEDICINE

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN®Basal-Bolus Type 1): 2-year results of a randomized clinical trial

(2013) B. W. Bode et al.   DIABETIC MEDICINE

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

(2013) Chantal Mathieu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial

(2013) Yukiko Onishi et al.   Journal of Diabetes Investigation

Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries

(2013) Petronella H. Geelhoed-Duijvestijn et al.   JOURNAL OF MEDICAL ECONOMICS

Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians

(2012) Meryl Brod et al.   CURRENT MEDICAL RESEARCH AND OPINION

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

(2012) J. H. DeVries et al.   DIABETES CARE

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

(2012) I. B. Hirsch et al.   DIABETES CARE

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries

(2012) K. Khunti et al.   DIABETES OBESITY & METABOLISM

A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study

(2012) K. Bowering et al.   DIABETIC MEDICINE

Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs

(2012) N. Hex et al.   DIABETIC MEDICINE

Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings

(2012) V. Pīrāgs et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Uncovering undetected hypoglycemic events

(2012) Jeffrey Unger   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Impaired awareness of hypoglycaemia: a review

(2011) A.J. Graveling et al.   DIABETES & METABOLISM

The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial: Comparing the durability of lispro mix 75/25 and glargine

(2011) J. B. Buse et al.   DIABETES CARE

An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study

(2011) Philip Home et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland

(2011) Jyrki K. Mäkelä et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Insulin analogues and severe hypoglycaemia in type 1 diabetes

(2011) P.L. Kristensen et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Strategies for insulin initiation: insights from the French LIGHT observational study

(2011) Bruno Vergès et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

(2011) Meryl Brod et al.   VALUE IN HEALTH

First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia

(2011) Shih-Tzer TSAI et al.   Journal of Diabetes

Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden

(2011) Kerstin Berntorp et al.   Primary Care Diabetes

Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial

(2010) William F. Miser et al.   CLINICAL THERAPEUTICS

Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes

(2010) S. M. Jain et al.   DIABETES OBESITY & METABOLISM

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial

(2010) Julio Rosenstock et al.   LANCET

Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease

(2009) M. F. Moen et al.   Clinical Journal of the American Society of Nephrology

Hypoglycaemia: An overview

(2009) Alex J. Graveling et al.   Primary Care Diabetes

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

(2008) A. Liebl et al.   DIABETES OBESITY & METABOLISM

Hypoglycaemia in Type 2 diabetes

(2008) S. A. Amiel et al.   DIABETIC MEDICINE

Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia

(2008) S. G. H. A. Swinnen et al.   DIABETOLOGIA